Flanvotumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameFlanvotumab
Drug Alias NameIMC-20-D-7-S20-D-7-S20-D-7
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTyrosinase-related protein 1 inhibitors
TargetsTyrosinase-related protein 1
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImclone SystemsEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG